Literature DB >> 7691065

FK506 and cyclosporin, molecular probes for studying intracellular signal transduction.

J Liu1.   

Abstract

The immunosuppressants cyclosporin and FK506 block the calcium-dependent signal-transduction pathway emanating from the T-cell receptor, thereby inhibiting the activation of helper T cells. Using these drugs as probes, chemists and biologists have uncovered several intracellular signaling molecules bridging the generation of second-messenger Ca2+ ion and the transcriptional activation of IL-2, among which are calmodulin, calcineurin and the nuclear factor of activated T cells (NF-AT). Hence, Ca2+ binds to calmodulin, leading to the binding of calmodulin to calcineurin; the activated calcineurin, in turn, may dephosphorylate the cytoplasmic subunit of NF-AT, resulting in its translocation from the cytoplasm into the nucleus to form a competent transcriptional activator. As described by Jun Liu these drugs manifest their effects in an unprecedented fashion. They do not directly intercept intracellular signaling molecules. Instead, they form tight complexes with two different classes of abundant cytosolic receptors called immunophilins upon entering the cell, and consequently inhibit their peptidyl prolyl cis-trans isomerase activities. The two structurally distinct immunophilin-drug complexes bind to, and inhibit, the phosphatase activity of calcineurin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691065     DOI: 10.1016/0167-5699(93)90048-P

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  53 in total

Review 1.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  [Systemic therapy of atopic dermatitis].

Authors:  A Heratizadeh; K Breuer; A Kapp; T Werfel
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

3.  Blockade of T-cell activation by dithiocarbamates involves novel mechanisms of inhibition of nuclear factor of activated T cells.

Authors:  S Martínez-Martínez; P Gómez del Arco; A L Armesilla; J Aramburu; C Luo; A Rao; J M Redondo
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

4.  Infusion of nonmyeloablative bone marrow alleviates acute rejection reaction in liver allotransplantation.

Authors:  Hai-yang Xie; Dong-sheng Huang; Chang-ku Jia; Shu-sen Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2005-12       Impact factor: 3.066

5.  Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506.

Authors:  C A Harrison; R Bastan; M J Peirce; M R Munday; P T Peachell
Journal:  Br J Pharmacol       Date:  2007-01-02       Impact factor: 8.739

6.  Tacrolimus-induced neurotoxicity and nephrotoxicity is ameliorated by administration in the dark phase in rats.

Authors:  Atsushi Yamauchi; Ryozo Oishi; Yasufumi Kataoka
Journal:  Cell Mol Neurobiol       Date:  2004-10       Impact factor: 5.046

7.  Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells.

Authors:  K T Shaw; A M Ho; A Raghavan; J Kim; J Jain; J Park; S Sharma; A Rao; P G Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

8.  Calcineurin, the Ca2+/calmodulin-dependent protein phosphatase, is essential in yeast mutants with cell integrity defects and in mutants that lack a functional vacuolar H(+)-ATPase.

Authors:  P Garrett-Engele; B Moilanen; M S Cyert
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

Review 9.  Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation.

Authors:  Jun O Liu
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

10.  Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors.

Authors:  J Van Wauwe; F Aerts; H Walter; M de Boer
Journal:  Inflamm Res       Date:  1995-09       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.